An Exposure-Response Perspective on the Clinical Dose of Pretomanid

Pretomanid was approved by the U.S. FDA, via the limited population pathway for antibacterial and antifungal drugs, as part of a three-drug regimen with bedaquiline and linezolid for the treatment of extensively drug-resistant and treatment-intolerant or nonresponsive multidrug-resistant tuberculosi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antimicrob Agents Chemother
Hlavní autoři: Nedelman, Jerry R., Salinger, David H., Subramoney, Vishak, Woolson, Rob, Wade, Karen, Li, Mengchun, Everitt, Daniel, Mendel, Carl M., Spigelman, Mel
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2020
Témata:
Clinical Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7927811/
https://ncbi.nlm.nih.gov/pubmed/33077660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01121-20
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky